


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Original) 2-(α -n-pentanonyl)benzoates having the following formula



wherein n is 1 or 2; M is a monovalent metal ion, a bivalent metal ion or an organic base group.

2. (Previously Presented) The 2-(α -n-pentanonyl)benzoates of claim 1, wherein M is a monovalent metal ion selected from the group consisting of Li⁺, Na⁺ and K⁺.

Claims 3-12. (Cancelled)

13. (Previously Presented) The 2-(α -n-pentanonyl)benzoates of claim 1, wherein M is selected from the group consisting of Na⁺, K⁺, Ca²⁺, and N,N'-dibenzylethylenediamine.

Claims 14-24. (Cancelled)

25. (Currently Amended) A pharmaceutical composition for treating ~~or preventing~~ cardio-cerebral ischemic diseases, alleviating the disturbance of cardio-cerebral circulation and inhibiting thrombosis, comprising a therapeutically effective amount of the 2-(α -n-pentanonyl)benzoates of claim 1, and one or more pharmaceutically acceptable carriers.

26. (Previously Presented) The pharmaceutical composition of claim 25, which is formulated into tablets, capsules, granules, intravenous injections, or lyophilized intravenous injections.